Cargando…
The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
It has been 18 months now since the world-wide outbreak of COVID 19 (Corona Virus Disease 19) and still the ongoing research is being done for disease specific medicines. During June 2020 to August 2020, an attempt was made to explore if an add-on Ayurveda regimen comprising of Dasamoolkadutrayadi K...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983476/ https://www.ncbi.nlm.nih.gov/pubmed/35400975 http://dx.doi.org/10.1016/j.jaim.2022.100575 |
_version_ | 1784681983625920512 |
---|---|
author | Wanjarkhedkar, Pankaj Sarade, Girish Purandare, Bharat Kelkar, Dhananjay |
author_facet | Wanjarkhedkar, Pankaj Sarade, Girish Purandare, Bharat Kelkar, Dhananjay |
author_sort | Wanjarkhedkar, Pankaj |
collection | PubMed |
description | It has been 18 months now since the world-wide outbreak of COVID 19 (Corona Virus Disease 19) and still the ongoing research is being done for disease specific medicines. During June 2020 to August 2020, an attempt was made to explore if an add-on Ayurveda regimen comprising of Dasamoolkadutrayadi Kashayam and Guluchyadi Kwatham in tablet forms can be prescribed along with standard of care; which has established the clinical evidence that there is advantage of accelerated symptomatic recovery, early discharge from hospital, reducing the duration of hospital stay. After informed consent the patients were followed up over 9 months after discharged from hospital. The purpose of the present extended study was to find the impact of disease even though patients were discharged after appropriate treatment and if there were any late effects in the add-on Ayurveda treatment group after 9 months as it was one of the first few formal studies world-wide; since there was no long term follow up data available. The study concluded that no additional late effects or symptoms or complications which were known in Post COVID phase; were observed in study group who received the add-on Ayurveda regimen as compared to the control group with conventional standard of care. |
format | Online Article Text |
id | pubmed-8983476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-89834762022-04-06 The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen Wanjarkhedkar, Pankaj Sarade, Girish Purandare, Bharat Kelkar, Dhananjay J Ayurveda Integr Med Short Communication It has been 18 months now since the world-wide outbreak of COVID 19 (Corona Virus Disease 19) and still the ongoing research is being done for disease specific medicines. During June 2020 to August 2020, an attempt was made to explore if an add-on Ayurveda regimen comprising of Dasamoolkadutrayadi Kashayam and Guluchyadi Kwatham in tablet forms can be prescribed along with standard of care; which has established the clinical evidence that there is advantage of accelerated symptomatic recovery, early discharge from hospital, reducing the duration of hospital stay. After informed consent the patients were followed up over 9 months after discharged from hospital. The purpose of the present extended study was to find the impact of disease even though patients were discharged after appropriate treatment and if there were any late effects in the add-on Ayurveda treatment group after 9 months as it was one of the first few formal studies world-wide; since there was no long term follow up data available. The study concluded that no additional late effects or symptoms or complications which were known in Post COVID phase; were observed in study group who received the add-on Ayurveda regimen as compared to the control group with conventional standard of care. Elsevier 2022 2022-04-06 /pmc/articles/PMC8983476/ /pubmed/35400975 http://dx.doi.org/10.1016/j.jaim.2022.100575 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Short Communication Wanjarkhedkar, Pankaj Sarade, Girish Purandare, Bharat Kelkar, Dhananjay The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen |
title | The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen |
title_full | The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen |
title_fullStr | The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen |
title_full_unstemmed | The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen |
title_short | The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen |
title_sort | post-covid 19 long term surveillance study sequel to an add-on ayurveda regimen |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983476/ https://www.ncbi.nlm.nih.gov/pubmed/35400975 http://dx.doi.org/10.1016/j.jaim.2022.100575 |
work_keys_str_mv | AT wanjarkhedkarpankaj thepostcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen AT saradegirish thepostcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen AT purandarebharat thepostcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen AT kelkardhananjay thepostcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen AT wanjarkhedkarpankaj postcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen AT saradegirish postcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen AT purandarebharat postcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen AT kelkardhananjay postcovid19longtermsurveillancestudysequeltoanaddonayurvedaregimen |